Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.

Tytuł :
A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Autorzy :
Koga T; a Unit of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.; b Center for Bioinformatics and Molecular Medicine , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.
Sumiyoshi R; a Unit of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.
Kawakami A; a Unit of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.
Yoshizaki K; c Department of Biomolecular Science and Regulation , The Institute of Scientific and Industrial Research, Osaka University , Osaka , Japan.
Pokaż więcej
Źródło :
Modern rheumatology [Mod Rheumatol] 2019 Mar; Vol. 29 (2), pp. 302-305. Date of Electronic Publication: 2019 Jan 14.
Typ publikacji :
Journal Article; Review
Język :
English
Imprint Name(s) :
Publication: <2014-> : Philadelphia, PA : Taylor & Francis
Original Publication: Tokyo, Japan : Spring-Verlag Tokyo, c2000-
MeSH Terms :
Castleman Disease*/diagnosis
Castleman Disease*/immunology
Castleman Disease*/therapy
Interleukin-6*/antagonists & inhibitors
Interleukin-6*/blood
Antibodies, Monoclonal, Humanized/*pharmacology
Glucocorticoids/*pharmacology
Antibodies/blood ; Herpesvirus 8, Human/immunology ; Humans ; Immunologic Factors/pharmacology ; Japan ; Prognosis ; Receptors, Interleukin-6/immunology ; Treatment Outcome
Contributed Indexing :
Keywords: Idiopathic multicentric Castleman's disease; interleukin-6; tocilizumab
Substance Nomenclature :
0 (Antibodies)
0 (Antibodies, Monoclonal, Humanized)
0 (Glucocorticoids)
0 (Immunologic Factors)
0 (Interleukin-6)
0 (Receptors, Interleukin-6)
I031V2H011 (tocilizumab)
SCR Disease Name :
Multi-centric Castleman's Disease
Entry Date(s) :
Date Created: 20181005 Date Completed: 20190503 Latest Revision: 20190503
Update Code :
20201020
DOI :
10.1080/14397595.2018.1532383
PMID :
30285516
Czasopismo naukowe
Castleman's disease (CD), a heterogeneous group of lymphoproliferative disorders, is divided into unicentric CD (UCD) and multicentric CD (MCD) based on the number of regions of enlarged lymph nodes with characteristic histopathologic features. The clinical pictures and treatment differ greatly between these UCD and MCD. In MCD, cases of human herpesvirus 8-negative patients with unknown etiology are defined as idiopathic MCD (iMCD). Most cases of UCD are treatable by surgical excision. The prognosis of iMCD varies, and it may be challenging to achieve remission. Glucocorticoids are initiated as the first choice for therapy, but for glucocorticoid-resistant cases, interleukin (IL)-6 inhibition is initiated. However, an IL-6 inhibitor is not effective for all iMCD cases, and refractory cases occur despite these treatments. In this review, we briefly summarize the role of IL-6 in iMCD, and we discuss the efficacy that has been reported for tocilizumab (TCZ), the anti-IL-6 receptor antibody, for patients with iMCD in Japan. Factors predicting the therapeutic response to IL-6 remain to be identified, and the verification of the long-term safety of IL-6 inhibition is needed.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies